TrialGynecologic oncology2019

A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.

Ursula A Matulonis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.